SCHEDULE: SR One Discloses 8% Stake in Odyssey Therapeutics

SR One Capital Management reports an 8% beneficial ownership stake in Odyssey Therapeutics following the company's IPO.

Summary

• SR One Capital Management and affiliated funds collectively hold 3,794,883 shares of Odyssey Therapeutics, Inc. common stock.
• This represents an 8.0% ownership stake based on 47,174,156 shares outstanding as of May 11, 2026.
• The holdings were acquired through a combination of private preferred stock conversions and direct purchases during the company's IPO at $18.00 per share.
• The reporting persons state the shares were acquired for investment purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure confirming the post-IPO ownership structure of a major shareholder.

Positives

• Significant institutional backing from a specialized life sciences investor.
• Successful conversion of multiple series of preferred stock into common equity upon the IPO.
• Demonstrated long-term commitment through participation in multiple private funding rounds prior to the IPO.

Negatives

• The reporting persons are subject to a 180-day lock-up agreement, restricting their ability to sell shares until mid-November 2026.
• The concentration of ownership in a single investment firm may influence future corporate governance decisions.

Risks

• Market volatility could impact the value of the investment.
• Future potential for the reporting persons to dispose of shares once the lock-up period expires.
• Reliance on the issuer's business prospects and growth-oriented strategy.

Future Outlook

The reporting persons intend to hold their shares for investment purposes but may evaluate their position based on market conditions and the issuer's business prospects, subject to a 180-day lock-up period.

Management Comments

• The reporting persons have no present plans for extraordinary corporate transactions, changes to the board, or material changes to the issuer's capitalization.

Industry Context

StockSavvy.ai notes that this filing is a standard post-IPO disclosure for venture capital firms in the biotechnology sector, signaling continued institutional support for Odyssey Therapeutics following its public debut.

Comparison to Industry Standards

• The 8% ownership stake is consistent with typical venture capital holdings in early-stage biotech companies post-IPO.
• The use of a 180-day lock-up agreement is standard practice for major shareholders in recent life sciences public offerings.

Corporate Governance

Stakeholder Impact

• Shareholders should note the significant concentration of ownership by SR One.
• The existence of registration rights may impact future liquidity if the Funds decide to sell large blocks of shares.

Next Steps

• Expiration of the 180-day lock-up period on November 7, 2026.
• Potential future filings if the reporting persons change their ownership stake or investment intent.

Key Dates

Keywords

Odyssey Therapeutics, SR One Capital, Schedule 13D, Biotech IPO, Institutional Ownership, Common Stock